Universal reference book for medicines
Product name: LANZAP ® (LANZAP)

Active substance: lansoprazole

Type: H + -K + -ATPase inhibitor.
Antiulcer drug
Manufacturer: DR.
REDDY`S LABORATORIES (India)
Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..

PHARMACHOLOGIC EFFECT
Antiulcer.
Specific inhibitor of H + -K + -ATPase. Acting in the final phase of the secretion of hydrochloric acid in the stomach, lansoprazole reduces acid production, regardless of the nature of the stimulating factor.
Possessing high lipophilicity, it easily penetrates into the parietal cells of the stomach, concentrates in them and has a cytoprotective effect, increasing oxygenation of the gastric mucosa and increasing secretion.

PHARMACOKINETICS
After oral administration, lansoprazole is absorbed from the digestive tract.
It is largely exposed to the effect of "first passage" through the liver. Although food reduces the absorption and bioavailability of lansoprazole, the inhibitory effect on the formation of hydrochloric acid remains the same before and after meals.
The binding with plasma proteins is 97.7-99.4%.

It is excreted from the body with bile and urine (only in the form of metabolites - lansoprazole-sulfone and hydroxylansoprazole);
while 24% of urine output is 14-23%. T 1/2 is 1.3-1.7 hours in healthy volunteers.
T 1/2 increases in patients with severe impairment of liver function and in patients older than 69 years.
In patients with impaired renal function, the absorption of lansoprazole remains practically unchanged.
INDICATIONS
Peptic ulcer of duodenum in the phase of exacerbation, peptic ulcer disease in the exacerbation phase, reflux esophagitis, Zollinger-Ellison syndrome;
eradication of Helicobacter pylori in the gastric mucosa in infected patients with peptic ulcer of the stomach and duodenum.
DOSING MODE
Take inside 30 mg 1-2 times / day.
The duration of the application depends on the indications and the scheme of therapy.
SIDE EFFECT
From the digestive system: diarrhea, abdominal pain;
rarely - constipation.
From the side of the central nervous system: headaches;
rarely - dizziness, drowsiness; in some cases - depression.
From the respiratory system: rarely - pharyngitis, rhinitis.

Other: skin rashes;
in some cases - myalgia.
CONTRAINDICATIONS
Pregnancy, lactation (breastfeeding), hypersensitivity to lansoprazole.

PREGNANCY AND LACTATION
Lansoprazole is contraindicated in pregnancy and lactation (breastfeeding).

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
Use with caution in patients with severe hepatic impairment.

APPLICATION FOR CHILDREN
The efficacy and safety of lansoprazole in children have not been studied.

SPECIAL INSTRUCTIONS
Use with caution in patients with severe hepatic impairment.

With caution and under strict medical supervision, lansoprazole should be used in patients receiving theophylline.

Antacids containing aluminum and magnesium hydroxides should be taken 2 hours after lansoprazole administration.
In patients with cirrhosis, lansoprazole excretion slows down.
The efficacy and safety of lansoprazole in children have not been studied.

DRUG INTERACTION
With simultaneous use with antacids moderately reduced bioavailability of lansoprazole.

With simultaneous use with amoxicillin, clarithromycin, metronidazole, glossitis, stomatitis and / or the appearance of a dark color of the tongue are possible.

With simultaneous use with warfarin, there are cases of increased anticoagulant action of warfarin.

There is evidence that with the simultaneous use of lansoprazole increases the duration of action of vecuronium.

With simultaneous use with carbamazepine, a decrease in the concentration of carbamazepine in the blood plasma is possible because of a decrease in its absorption from the gastrointestinal tract due to a decrease in the pH of the stomach contents under the influence of lansoprazole.
This can lead to a decrease in the clinical efficacy of carbamazepine.
It is believed that lansoprazole, when used at the same time, may decrease the bioavailability of ketoconazole due to a decrease in the acidity of the contents of the stomach under the influence of proton pump inhibitors.

It is believed that with simultaneous use with lansoprazole may increase the toxicity of methotrexate.

With simultaneous application, a slight increase in the clearance of theophylline is possible.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!